ProMIS reaffirms Q1 2027 PRECISE-AD data timing, reports Q3 2026 results
The company said patient visits in its Phase 1b Alzheimer's trial are closing out, with cash of $44.1 million expected to fund operations through 2027.
ProMIS Neurosciences reported financial results for the third quarter of 2026 on November 12, 2026, and reaffirmed the timing of topline data from its PRECISE-AD trial.
The company said PRECISE-AD is closing out its final stage of patient visits, with topline data reporting expected in the first quarter of 2027, including safety, biomarker and clinical efficacy measures.1 Completion of all patient visits is expected in the fourth quarter of 2026.1
On July 28, 2026, ProMIS reported interim data from the blinded trial. In 136 patients, the company observed no ARIA-E as of the data cutoff in any APOE genotype (including 11% APOE4 homozygotes), ARIA-H of 4.4% (all mild and asymptomatic), no drug-related discontinuations or treatment-related serious adverse events, and a decrease from baseline of approximately 15% in plasma pTau217 and 13.3% in CSF MTBR-tau243 in the pooled, blinded population.1
On regulatory plans, the company said PMN310's Fast Track Designation allows for more frequent engagement with the FDA, and it plans to request a meeting with the agency next year, after the full data set has been analyzed.1 ProMIS is also advancing development of a subcutaneous formulation of PMN310 and preparing for a registrational study that, subject to FDA feedback, it anticipates initiating toward the end of 2027.1
On personnel, ProMIS appointed Ivana Rubino, Ph.D., a former senior Biogen and Roche executive with more than 15 years of global neuroscience and Alzheimer's disease leadership experience, as Chief Commercial Officer, effective October 5, 2026.1
On finances, cash was $44.1 million as of September 30, 2026, compared to $6.1 million as of December 31, 2025, reflecting net proceeds of $70.1 million from the company's January 2026 private placement.1 The company said existing cash will be sufficient to fund operating expenses and capital expenditure requirements through 2027, well beyond the anticipated first quarter 2027 PRECISE-AD topline data readout.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.